A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TERRANOVA
- Sponsors AstraZeneca
- 19 Apr 2018 This trial has been completed in Bulgaria (End date: 2018-04-09).
- 17 Apr 2018 This trial has been completed in Poland.
- 14 Apr 2018 This trial has been completed in Sweden (end date: 2018-04-09)